
This study evaluates Alzheimer's prognostic covariates (APCs) in lecanemab trials to reduce variability in treatment effect assessments. Using APCs derived from clinical and MRI data decreased variance by 19.1%, increased power to 90.2%, and reduced sample size by 27.2%. These findings highlight APCs as valuable tools for improving statistical power and efficiency in AD clinical trials.
Like
Save
Share